跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TH-34
首页
药物
TH-34
TH-34
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
US 2004082506 A1
申请人: YAMASHITA TAKEYOSHI
优先权: 2000
CN
US
2 件公开
Bispecific antibody targeting MSLN and 4-1BB and application thereof
CN 116769041 A
申请人: HEFEI HANKEMAB BIOTECHNOLOGY CO LTD
优先权: 2022
CN
广谱中和SARS-CoV-2以及其他沙贝病毒的抗体及其应用
CN 117327173 B
申请人: 清华大学
优先权: 2022
CN
Orthogonally modified human serum albumin as well as preparation method and application thereof
CN 118005768 A
申请人: UNIV EAST CHINA SCIENCE & TECH
优先权: 2022
CN
Specific antibody for resisting glycocholic acid-antibody compound and application thereof
CN 120988136 A
申请人: HANGZHOU EACTION BIOTECHNOLOGY CO LTD
优先权: 2025
CN
Immune globulin light chain mutant, nucleotide, recombinant expression vector and application
CN 121758600 A
申请人: UNIV SHANGHAI SCIENCE & TECH
优先权: 2025
CN
Anti-pseudorabies virus gD protein neutralizing monoclonal antibody as well as preparation method and application thereof
CN 122080186 A
申请人: UNIV JILIN
优先权: 2026
CN
药物
反馈